Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatment options for people living with HIV-1, focusing on improving the current standard of care. The study compares a new once-weekly antiretroviral therapy ART combining islatravir and ulonivirine to the standard daily ART regimen, which includes multiple medications taken up to twice a day. This research aims to evaluate if the new study ART works as well as the current standard treatment, while also assessing its safety and how well participants tolerate it. Participants will be randomly assigned to one of several groups one group will receive the study drugs islatravir and ulonivirine once weekly, another will take the standard ART daily, and two additional groups will receive combinations of study drugs and placebos for 96 weeks. The study involves both phase 2 and phase 3 parts, with participants taking their assigned medication orally either once daily or once weekly during this period. Throughout the study, participants will attend regular visits for up to 96 weeks where researchers will monitor their HIV-1 RNA levels, CD4 T-cell counts, body weight, and any adverse events. The main measurement is the percentage of participants with HIV-1 RNA below 50 copiesmL at weeks 24 and 48 for phase 2 and phase 3 respectively. Safety and tolerability will also be closely observed, including any discontinuation due to adverse events. Participants health will be followed through various laboratory tests and assessments during the study period.
Actively Recruiting
Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.
Actively Recruiting
Researchers are evaluating the effectiveness of switching to the study drugs GS-3242 combined with Lenacapavir LEN compared to continuing the standard treatment Biktarvy bictegraviremtricitabinetenofovir alafenamide, BFTAF in adults with HIV-1 infection who are virologically suppressed. This Phase 2 randomized study aims to assess the safety and efficacy of an injectable regimen of GS-3242 plus LEN versus oral BFTAF in different treatment groups over distinct time points, with Part A focusing on Week 35 and Part B on Week 26. Participants are randomly assigned to receive either oral loading doses of GS-3242 and LEN tablets followed by intramuscular IM injections of these drugs for up to 52 weeks, or to continue daily oral BFTAF for the same duration. Different dosing regimens of GS-3242 and LEN are used across groups, with some groups receiving different IM doses. The study includes both randomized and non-randomized groups across the two parts. During the study, participants will be monitored for viral load, specifically HIV-1 RNA levels, using the US FDA Snapshot Algorithm at Weeks 26, 35, and 52, as well as CD4 cell counts. Safety is assessed by recording treatment-emergent adverse events throughout the study period. Drug concentrations are also measured at specific weeks to evaluate pharmacokinetics. The total participant involvement can last up to 52 weeks, with regular assessments to evaluate treatment efficacy and safety.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of two drug combinations Cabotegravir Ultra Long-Acting CAB ULA plus Rilpivirine Ultra Long-Acting RPV ULA, and Cabotegravir Long-Acting CAB LA plus Rilpivirine Long-Acting RPV LA in adults and adolescents living with HIV who have their virus suppressed through antiretroviral therapy ART. This phase III trial aims to compare these treatments to understand their impact on maintaining viral suppression. Participants receive either the CAB ULA plus RPV ULA combination or the CAB LA plus RPV LA combination. These medications are administered as long-acting injectable drugs. The study uses a randomized, parallel-group design where participants are assigned to one of these two treatment groups to compare outcomes over time. During the trial, participants will be monitored closely with regular assessments including measuring plasma HIV-RNA levels, tracking any virologic failure, and evaluating drug-related adverse events. Laboratory tests will monitor drug concentrations and immune cell counts CD4 cells. The main outcome is the percentage of participants with HIV-RNA levels above 50 copiesmL at month 11. The study follows participants for up to 23 months to assess longer-term effects and safety.
Actively Recruiting
This research aims to evaluate a rapid restart approach of antiretroviral therapy ART for people living with HIV who have stopped treatment for at least 12 weeks. Many individuals face challenges such as side effects, stigma, or difficulty accessing care, which can cause interruptions in their HIV treatment. The study focuses on whether starting treatment quickly with BFTAF, a once-daily oral HIV medication, is safe and effective in helping participants regain control of their HIV and stay engaged in care. Participants will receive the study drug BFTAF, which combines bictegravir, emtricitabine, and tenofovir alafenamide, taken once daily. Those with a higher viral load at the start will take the medication for 48 weeks, while those with suppressed viral load will take it for 24 weeks. The treatment begins on the same day participants return to care, without waiting for baseline lab results, enabling a rapid restart. The study includes two groups viremic participants with HIV-1 RNA 50 copiesmL and virologically suppressed participants with HIV-1 RNA <50 copiesmL. During the study, participants will be monitored through regular assessments for up to 48 weeks depending on their group. Researchers will measure viral load suppression, treatment safety, adherence, resistance, and patient experiences. A subset of participants will also take part in interviews to better understand reasons for stopping and restarting treatment. The study aims to provide insights that could improve support for people living with HIV facing treatment interruptions.
Actively Recruiting
Researchers are evaluating an injectable regimen combining GS-3242 and Lenacapavir LEN compared to the oral drug Biktarvy BFTAF in people with HIV-1 who have not previously received treatment. This study includes Phase 2 and Phase 3 portions with different groups to compare the effectiveness of these treatments over several weeks. The main goal is to measure how well these treatments reduce HIV-1 RNA levels in the blood at specified weeks. Study participants will be assigned to receive either oral loading doses of GS-3242 combined with LEN tablets followed by intramuscular IM injections of both drugs for durations of at least 52 or 104 weeks, depending on the group, or daily oral doses of BFTAF for similar periods. The study includes several treatment groups with varying doses and schedules to assess differences between the injectable and oral regimens. Participants will be monitored regularly with assessments including measuring HIV-1 RNA levels using the US FDA Snapshot Algorithm at weeks 12, 26, 35, 52, and 104, and tracking changes in CD4 cell counts from baseline. Safety is monitored by recording treatment-emergent adverse events throughout the study. The total participation time may extend up to 104 weeks, with frequent visits for medication administration and evaluation of treatment effectiveness and safety.
Actively Recruiting
Researchers are evaluating a new long-acting injectable treatment combining lenacapavir LEN, teropavimab TAB, and zinlirvimab ZAB compared to injections of cabotegravir CAB and rilpivirine RPV given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment. The study aims to determine which regimen better maintains viral suppression after one year 52 weeks of treatment. Participants will be randomly assigned to one of two groups. One group receives oral LEN on Day 1, subcutaneous LEN and intravenous infusions of TAB and ZAB on Day 1, then oral LEN on Day 2, followed by subcutaneous LEN and IV infusions of TAB and ZAB every 26 weeks up to Week 92. The other group discontinues their current oral therapy and receives intramuscular injections of CAB and RPV on Day 1, Week 4, and then every 8 weeks up to Week 92. After Week 92, eligible participants may continue LEN TAB ZAB in an extension phase until its completion or discontinuation. During the study, participants will undergo regular monitoring of their HIV-1 RNA levels to assess viral suppression, along with measurements of CD4 T-cell counts. Safety is tracked through adverse event reports and blood tests. The primary outcome is the proportion of participants with HIV-1 RNA at or above 50 copiesmL at Week 52. Secondary outcomes include viral load at Week 92, immune cell changes, drug concentration levels, and antibody development. The total study duration extends up to approximately seven years, including follow-up and extension phases.
Actively Recruiting
This trial investigates long-acting oral regimens for people with HIV-1 who have controlled virus levels. The study focuses on evaluating safety, tolerability, effectiveness, and how the body processes these regimens compared to continuing a daily oral treatment. It specifically examines switching to weekly long-acting oral combinations including GS-3242 plus Lenacapavir versus continuing the daily oral combination of bictegraviremtricitabinetenofovir alafenamide BFTAF. Participants are assigned to one of three groups continuing daily BFTAF for at least 48 weeks, or switching to one of two doses of the weekly oral GS-3242 plus Lenacapavir regimen for at least 48 weeks. After this randomized phase, participants may have the option to continue receiving their assigned study treatment during an extension phase. Throughout the study, participants provide blood samples to monitor HIV-1 RNA levels, CD4 cell counts, and drug levels in the body. Researchers assess safety by tracking adverse events and measure how well the virus remains suppressed at weeks 12, 24, and 48. The total study duration includes at least 48 weeks of treatment, with ongoing follow-up, to evaluate the long-term effects and tolerability of the regimens.